Readers might be interested to know a safe and apparently effective treatment for WNV encephalitis was published three years ago.
My company developed (and owns a patent which is still pending) on the treatment, and has been using it in an ongoing free clinical trial for the past 5 summers, since 2003.
Our initial results on 8 patients seen in Sept, 2003 were published in a peer-reviewed medical journal in July, 2004 (1). Publication in a peer-reviewed medical journal is all that’s required for a treatment to officially exist, even if the public health authorities omit to mention it.
21 patients with WNV have responded so far, out of 25 (84%). We’ve also treated 4 horses (3 responded) and 12 birds (6 responded; birds present sicker than humans and horses). Our WNV trial is free from our end. The blood pressure meds we use are inexpensive (around $1/day) and are available by prescription from any drugstore in the country.
Anybody who wants to download our trial documents can do so at any time of day or night from our homepage at www.genomed.com.
Beginning treatment early—within the first 48 hrs of encephalitis symptoms—seems to be the only way to avoid long-term sequelae such as paralysis, chronic fatigue, cognitive problems, etc. WNV is notorious for still affecting half of WNV victims 18 months later.
If a family knows about our treatment ahead of time, they’ll be in a much better position to get it prescribed for their relative who comes down with the disease.
Reference
1. Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: http://www.genomed.com/index.cfm?action=investor&drill=publications)
Sincerely,
Dave Moskowitz MD
Chairman, CEO & Chief Medical Officer
GenoMed, Inc.
“Our business is public health(TM)”
website: www.genomed.com
Ticker symbol: GMED.PK (on the OTC Pink Sheets)
email: dwmoskowitz@genomed.com